June 19^th, 2007
DeveloGen and Teva Enter into Exclusive License Agreement for DeveloGen's Protein Kinase B Technology for the Treatment of Cancer

(62 KB)

June 14^th, 2007
DeveloGen Israel Limited ("DeveloGen"), a wholly owned subsidiary of DeveloGen AG, and Andromeda Biotech Ltd. ("Andromeda"), a newly formed wholly owned subsidiary of Clal Biotechnology Industries Ltd. ("CBI"), today announced that DeveloGen and Andromeda have completed the final agreement for an asset purchase agreement for DeveloGen's DiaPep277® program for the treatment of type 1 diabetes.

(69 KB)

April 17^th, 2007
DeveloGen and Andromeda, a newly formed wholly-owned subsidiary of Clal Biotechnology Industries, Sign Term Sheet for Asset Purchase Agreement for the DiaPep277® Program

(69 KB)

July 4^th, 2006
DeveloGen receives Grant for DiaPep277® Program

(69 KB)

June 21^st, 2006
DiaPep277® mechanism of action demonstrated

(55 KB)

June 13^th, 2006
DeveloGen AG and its CEO, Dr. Guenther Karmann, part by mutual agreement; Dr. Cord Dohrmann, CSO, appointed to the Management Board

(63 KB)

January 31^st, 2006
DeveloGen receives JDRF Grant for Beta-Cell Regeneration Program

(129 KB)

January 11^th, 2006
DeveloGen Announces Changes to Scientific Advisory Board

(97 KB)

October 5^th 2005
DeveloGen Announces End-of-Phase II Meeting with FDA, EMEA Scientific Advice Meeting and First-Patient-In for Phase III Clinical Trial of DiaPep277^®

(132 KB)

September 14^th 2005
DeveloGen presents positive Phase II Data at EASD Conference

(139 KB)

August 16^th 2005
DeveloGen and Debiopharm Announce Partnering of Myasthenia Gravis Program

(137 KB)

August 3^rd 2005
DeveloGen supports zell-kontakt with its award of the Innovationspreis 2004 (german language only)

(324 KB)

Image - from left to right: Dr. Dohrmann/CSO DeveloGen, Landrat Mr. Schermann, Dr. Busse/zell-kontakt

(87 KB)

June 1^st, 2005
DeveloGen appoints New Scientific Advisory Board and announces Changes in Senior Management Team

(107 KB)

November 9^th, 2004
DeveloGen receives R&D Funds for Diabetic Complications Project

(76 KB)

May 17^th, 2004
DeveloGen completes 19 Million Euro Financing Round

(107 KB)

November 13^th, 2003
Peptor and DeveloGen announce intention to merge

(215 KB)

September 10^th, 2003
DeveloGen and Evotec OAI announce a Strategic Drug Discovery and Development Alliance for Metabolic Diseases

(56 KB)

10. April 2003
DeveloGen AG und das Max-Planck-Institut für biophysikalische Chemie erhalten den Kooperationspreis des Landes Niedersachsen 2002

(650 KB)

January 17^th, 2003
DeveloGen and Scientists from IPK Gatersleben Publish Data on Key Trigger for Regenerating Insulin Producing Cells.

(58 KB)

September 3^rd, 2002
DeveloGen appoints Dr. Klaus Brandau as Chairman of the Supervisory Board.

(68 KB)

July 30, 2002
"Aventis and Peptor Limited Sign Agreement for the License, Development and Commercialisation of New Diabetes Therapy"

(136 KB)

April 17^th, 2002
DeveloGen names Dr. Guenther Karmann as CEO.

(103 KB)

March 27^th, 2002
DeveloGen Announces Support of Diabetes Research by the European Comission.

(94 KB)

March 6^th, 2002
DeveloGen Announces Senior Management Appointments in Business Development and Research.

(92 KB)

Jan, 2002
"U.S. clinical trial begins for DiaPep277®, new drug shown to arrest progression of type 1 diabetes"

(16 KB)

September 9^th, 2001
Glasgow EASD

(8)

April 18^th, 2001
DeveloGen Closes Euro 40 Million Private Financing.

(95 KB)

October 5^th, 2000
DeveloGen Completes Merger with HepaVec and Appoints Finance Director.

(97 KB)

May 16^th, 2000
DeveloGen and HepaVec Combine in Germany's First Biotech-to-Biotech Merger.

(87 KB)

December 8^th, 1999
DeveloGen Scientific Co-founders Awarded German Future Award for Achievement in Technology and Innovation.

(81 KB)

January 19^th, 1998
DeveloGen Receives $3 Million to Target Control Genes in the Fight against Diabetes and Obesity.

(63 KB)